Have a feature idea you'd love to see implemented?
Let us know!
BBIO BridgeBio Pharma Inc
Price (delayed)
$23.24
Market cap
$4.39B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.41
Enterprise value
$5.72B
BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in
Highlights
BBIO's EPS is up by 38% year-on-year and by 8% since the previous quarter
BridgeBio Pharma's gross margin has increased by 35% YoY
BridgeBio Pharma's quick ratio has decreased by 45% YoY and by 33% from the previous quarter
BBIO's equity is down by 13% since the previous quarter
Key stats
What are the main financial stats of BBIO
Market
Valuations
Earnings
Shares outstanding
188.99M
Market cap
$4.39B
Enterprise value
$5.72B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
20.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.25
Revenue
$217.77M
EBIT
-$349.12M
EBITDA
-$338.7M
Free cash flow
-$451.54M
Per share
Balance sheet
Liquidity
EPS
-$2.41
Free cash flow per share
-$2.4
Book value per share
-$6.54
Revenue per share
$1.16
TBVPS
$3.4
Total assets
$664.98M
Total liabilities
$1.88B
Debt
$1.73B
Equity
-$1.23B
Working capital
$305.36M
Debt to equity
-1.41
Current ratio
3.19
Quick ratio
2.92
Net debt/EBITDA
-3.91
Margins
Efficiency
Dividend
EBITDA margin
-155.5%
Gross margin
98.9%
Net margin
-201.5%
Operating margin
-245.6%
Return on assets
-61.5%
Return on equity
N/A
Return on invested capital
-19.1%
Return on capital employed
-66.4%
Return on sales
-160.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BBIO stock price
How has the BridgeBio Pharma stock price performed over time
Intraday
0.87%
1 week
-3.61%
1 month
-7.63%
1 year
-17.91%
YTD
-42.43%
QTD
-8.72%
Financial performance
How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$217.77M
Gross profit
$215.37M
Operating income
-$534.88M
Net income
-$438.86M
Gross margin
98.9%
Net margin
-201.5%
BBIO's net margin has surged by 97% year-on-year and by 2.7% since the previous quarter
BBIO's operating margin has soared by 96% YoY but it is down by 7% QoQ
BridgeBio Pharma's gross margin has increased by 35% YoY
BBIO's net income is up by 28% year-on-year and by 3.3% since the previous quarter
Growth
What is BridgeBio Pharma's growth rate over time
Valuation
What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
20.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.25
BBIO's EPS is up by 38% year-on-year and by 8% since the previous quarter
BBIO's equity is down by 13% since the previous quarter
The stock's price to sales (P/S) is 91% less than its 5-year quarterly average of 229.2 and 90% less than its last 4 quarters average of 193.9
Efficiency
How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 97% year-on-year and by 4.2% since the previous quarter
The ROA has grown by 40% YoY and by 3.6% from the previous quarter
The ROIC has grown by 36% YoY and by 6% from the previous quarter
Dividends
What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BBIO.
Financial health
How did BridgeBio Pharma financials performed over time
BBIO's total assets is 65% smaller than its total liabilities
BridgeBio Pharma's quick ratio has decreased by 45% YoY and by 33% from the previous quarter
The current ratio has decreased by 42% YoY and by 31% QoQ
BBIO's equity is down by 13% since the previous quarter
BBIO's debt to equity is up by 11% since the previous quarter and by 2.1% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.